How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

VSV/NDV hybrid virus for oncolytic therapy of cancer

Organization name

Bayerische Patentallianz GmbH

Profile

Background

Oncolytic virotherapy for cancer has emerged as a novel and promising therapeutic approach to replace standard cancer therapies, which often provide limited efficacy at the cost of un-pleasant or severe side effects. Oncolytic viruses have either an inherent ability to selectively kill cancer cells or are genetically engineered to preferentially replicate in cancer cells. Al-though several therapeutic virus platforms have recently found their way into the clinic, the widespread use of oncolytic virotherapy has been greatly limited by several challenges, includ-ing safety concerns. Thus, there is an urgent need to develop a new generation of oncolytic vectors to overcome the hurdles and exploit the therapeutic potential of virotherapy.

Innovation

Here, a novel VSV/NDV hybrid virus was engineered that combines the advantages of both vesicular stomatitis virus (VSV) and Newcastle disease virus (NDV) vectors, while the safety concerns of both are eliminated. Although VSV vectors are known for their rapid replication cycle and tumor cell killing, neurotoxic effects at elevated doses have hampered their clinical development. NDV vectors cause no dose limiting toxicities in humans, and mediate an efficient mechanism of intratumoral virus spread and tumor cell killing through fusion of the infected cells to the neighboring cells; however, the clinical development of NDV as an oncolytic vector has been restricted due to the environmental risk for birds and the poultry industry, as NDV is a natural avian pathogen. The VSV/NDV hybrid virus effectively overcomes the safety concerns of each parental virus, while maintaining efficient tumor cell killing.

Commercial Opportunities

Oncolytic virotherapy has many advantages compared to the conventional treatment options, such as chemotherapy and radiotherapy. It is expected that oncolytic therapy reduces severe side effects and efficiently eliminates tumor cells through its dual mechanism of action: On the one hand tumor cells are directly lysed by viral infection, and on the other hand, the virus can induce an immune response against the tumor to result in long-lasting systemic immunity. The VSV/NDV hybrid vector can efficiently replicate in cancer cells which are defective in their type I interferon signaling pathways, and therefore can be applied to a wide variety of tumors which bear this feature.

Developmental Status

Proof-of-concept in vitro. In vivo experiments are currently being performed.

Patent Status

PCT application 19/05/2016

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries